Connect with us

JAMMU & KASHMIR

Make Tocilizumab available for COVID-19 patients: DAK to authorities | KNO

Published

on

kno news

Srinagar, July 28 (KNO): Doctors Association Kashmir (DAK) on Tuesday urged concerned authorities in Kashmir Valley to make life-saving drug Tocilizumab available for critically-ill COVID-19 patients. “The drug reduces the risk of death in seriously ill Covid-19 patients,” said DAK President and influenza expert Dr Nisar ul Hassan in a statement issued to the news agency—Kashmir News Observer (KNO). Quoting a study from the University of Michigan, he said COVID-19 patients on ventilators who received a single dose of Tocilizumab injection were 45 percent less likely to die compared to those who did not receive the drug. “Originally developed to treat rheumatoid arthritis, the drug combats the disease by quelling cytokine storm which is the hyperimmune response of the infected person to the virus,” Dr Nisar said. “Mortality in Covid-19 patients has been linked to the presence of the cytokine storm induced by the virus,” he said adding that “excessive production of cytokines leads to respiratory failure and widespread tissue damage resulting in multiorgan failure and death.” Dr Nisar said Tocilizumab suppresses the hyperimmune response by blocking receptor for a key cytokine known as interleukin-6 (IL-6) and improves survival rates and reduces mortality among COVID patients. “Recently Indian Council of Medical Research (ICMR) in its revised protocol has allowed usage of the drug for patients with progressively increasing oxygen requirements and in mechanically ventilated patients not improving despite the use of steroids,” he said. Dr Nisar said it is vitally important to know that there is no single magic bullet to treat the novel Coronavirus and several drugs in combination are needed to tackle the virus. “With the approval of several therapies, combination of them given at the right time gives a good result,” he said. “Apart from oxygen, moderate to severe patients are given steroids, remdesivir, convalescent plasma and Tocilizumab in various combinations,” he added. “Initially it was believed that deaths were happening because of poor oxygenation. Now we know that intravascular clotting can also lead to lung dysfunction and death. So heparin is given in Covid patients to prevent clotting,” said Dr Nisar—(KNO)

Trending

TOP STORIES4 hours ago

Terrorism enemy of development, society needs to standup against terror sympathisers: LG Sinha | KNO

TOP STORIES4 hours ago

Not everyone in J&K is a terrorist: CM Omar on Delhi blast case | KNO

TOP STORIES9 hours ago

At minus 2.1°C, Sgr records coldest night of season | KNO

TOP STORIES10 hours ago

Delhi Blast Case: CIK raids 13 locations across Kashmir | KNO

TOP STORIES20 hours ago

DGP Prabhat orders attachment of Mian Qayoom’s immovable property in Srinagar | KNO

TOP STORIES21 hours ago

Centre declares Delhi Red Fort blast as “heinous terror incident”, passes resolution | KNO

TOP STORIES21 hours ago

LG Sinha calls on filmmakers to showcase J&K’s journey of peace | KNO

TOP STORIES21 hours ago

J&K Police heighten security in wake of Delhi blast; launch crackdowns on banned JeI in Kashmir | KNO

TOP STORIES21 hours ago

Sgr records season's coldest night at minus 1.6°C | KNO

TOP STORIES21 hours ago

Police tighten social media watch across valley, one booked | KNO

TOP STORIES21 hours ago

Steady rise in HIV cases in J&K: 117 patients registered in three months | KNO

TOP STORIES21 hours ago

‘World Pneumonia Day’: Immunocompromised individuals at greater risk of pneumonia: Experts | KNO

TOP STORIES21 hours ago

Mehbooba seeks fair probe into Delhi blast | KNO

TOP STORIES21 hours ago

JMC seizes 500 kg of substandard meat, fines vendors in major crackdown | KNO

TOP STORIES21 hours ago

MLA Kar concerned over deteriorating infra in educational institutions | KNO

TOP STORIES21 hours ago

Residents allege LCMA ‘stalling’ construction permissions | KNO

TOP STORIES21 hours ago

Two-day national conference begins at GDCW Sopore | KNO

Copyright © 2021